Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease |
| |
Authors: | Mohammad Tabrizi Gadi Gazit Bornstein Hamza Suria |
| |
Institution: | 1Preclinical Development (MT) and Corporate Development (HS), AnaptysBio, Inc., 10835 Road to the Cure, Suite 100, San Diego, California 92121 USA ;2Cancer Biologics, Astrazeneca R&D Boston, PLC, 35 Gatehouse Drive, Waltham, Massachusetts 02451 USA |
| |
Abstract: | The monoclonal antibody market continues to witness an impressive rate of growth and has become the leading source of expansion in the biologic segment within the pharmaceutical industry. Currently marketed monoclonal antibodies target a diverse array of antigens. These antigens are distributed in a variety of tissues such as tumors, lungs, synovial fluid, psoriatic plaques, and lymph nodes. As the concentration of drug at the proximity of the biological receptor determines the magnitude of the observed pharmacological responses, a significant consideration in effective therapeutic application of monoclonal antibodies is a thorough understanding of the processes that regulate antibody biodistribution. Monoclonal antibody distribution is affected by factors such as molecular weight, blood flow, tissue and tumor heterogeneity, structure and porosity, target antigen density, turnover rate, and the target antigen expression profile. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|